In clinical trials, SGLT2-Is reduced the risk of dialysis, transplantation, or death due to kidney disease in individuals with T2DM and also provided protection against acute kidney injury with consistent benefits across studies. Here, SLC5A2 is linked to type 2 diabetes mellitus.